Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03425188 · ClinicalTrials.gov registry record

Post Approval Study of the remedē System

A clinical trial of Central Sleep Apnea, sponsored by Respicardia.

Completed
Registry status
53
Enrollment target
17
Study locations

NCT03425188 is a study of Central Sleep Apnea that has completed, run by Respicardia. The registered enrollment target is 53 participants, below the 137-participant average among 4 other Central Sleep Apnea trials with a reported enrollment target (61% lower). The trial reports 17 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03425188, a study of Central Sleep Apnea, has completed, sponsored by Respicardia.

COMPLETED
Registry status
53 participants
Enrollment target
17
Study locations

Study Summary

Prospective, single arm cohort study to evaluate the long-term safety, long-term effectiveness, and survival rate in subjects implanted with the remedē System.

Conditions Studied

Study Locations (17)

Missouri

  • Saint Luke's Hospital of Kansas City - Kansas City
  • Washington University in St. Louis - St Louis

Ohio

  • The Lindner Center for Research & Education at The Christ Hospital - Cincinnati
  • The Ohio State University - Columbus

California

  • Keck Medical Center of USC - Los Angeles

Florida

  • UF Health Jacksonville - Jacksonville

Illinois

  • Advocate Good Samaritan Hospital - Downers Grove

Maryland

  • University of Maryland, Baltimore - Baltimore

Minnesota

  • United Heart and Vascular Clinic - Saint Paul

Nebraska

  • Nebraska Heart Institute - Lincoln

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2018-06-28
Est. Completion 2020-08-04

Sponsor

Respicardia

8 total trials

What the Registry Record Tells You About NCT03425188

The ClinicalTrials.gov registry entry for NCT03425188 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 4 other Central Sleep Apnea trials with a reported enrollment target (61% lower). The listed sponsor is Respicardia, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Central Sleep Apnea appearing as the primary indexed condition, and to 0 interventions.

NCT03425188 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Missouri, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT03425188 about?

NCT03425188 is a clinical study titled "Post Approval Study of the remedē System". Prospective, single arm cohort study to evaluate the long-term safety, long-term effectiveness, and survival rate in subjects implanted with the remedē System.

What is the current status of trial NCT03425188?

This trial is currently completed. The enrollment target is 53 participants. The study started on 2018-06-28. Estimated completion is 2020-08-04.

What conditions does trial NCT03425188 study?

This clinical trial studies the following conditions: Central Sleep Apnea.

Who is sponsoring clinical trial NCT03425188?

This trial is sponsored by Respicardia, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03425188 being conducted?

This trial has 17 study locations across California, Florida, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Central Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.